As part of a multi-state settlement with pharmaceutical companies Teva and Allergan, as well as retailers CVS and Walgreens, the State of Idaho will receive $76 million to aid in the battle against the opioid crisis.
The firms will pay $17.3 billion in total as part of the deal. Walgreens will pay $5.7 billion, while CVS will pay $5 billion, according to reports. Allergan and Teva, two producers of opioids, will each pay $2.37 billion and $4.25 billion, respectively. Idaho will receive $76 million over 15 years, and funding for state and local governments is anticipated to begin flowing by the end of 2023.
According to Idaho's AG, the pharmaceutical industry has made money for years by selling and distributing harmful opioids. Unrestricted access to these substances has wreaked havoc on our neighborhoods. This agreement holds the whole industry accountable and shows our dedication to altering the ways in which opioid medicine manufacturers and their distributors conduct business.
In accordance with the agreements, Teva's opioid division must also offer strict injunctive relief to stop all opioid marketing and guarantee that safeguards are in place against drug abuse. Additionally, Allergan must stop marketing opioids for the following ten years.
Pharmacies CVS and Walgreens have committed to monitoring, reporting, and exchanging information about any questionable behavior involving opioid prescriptions.
Attorneys General from North Carolina, Iowa, California, Illinois, Maryland, Massachusetts, New York, Pennsylvania, Tennessee, Texas, Vermont, Virginia, and Wisconsin led discussions with Teva and Allergan.
Attorneys General from North Carolina, California, Colorado, Connecticut, Delaware, Illinois, Indiana, Iowa, Kentucky, Louisiana, Massachusetts, Nebraska, New York, Ohio, Pennsylvania, Rhode Island, Tennessee, and Texas were in charge of the discussions with CVS and Walgreens.
